E4-Diagnose is the new innovative instrumentation device providing an unprecedented opportunity to evaluate quantitatively the endothelial function in a human body with noninvasive, simple, cost-effective, mobile & field usable and maintainable apparel. E4-Diagnose has been created from listening to the needs of Tunisian cardiologists and has been developed with their support and full involvement to tailor it to their specific needs and constraints. It provides the precision and accuracy in the measurements and outputs variables to establish a proper identification of the behavior and state of the endothelial function.
E4-Diagnose has been developed jointly with eminent cardiologists in Tunisia and expert nurses with, in mind, the patient journey in a cardiologist consult. This medical collaboration allowed to target precisely the needs of both users of the device (Cardiologists for diagnostic and Nurses for using it) and to tailor the device to their constraints and the constraints of the consult journey.
S. Charfessdine & al : Long COVID 19 Syndrome: Is It Related to Microcirculation and Endothelial Dysfunction? Insights From TUN-EndCOV Study.
The COVID-19 disease is a multisystem disease due in part to the vascular endothelium injury. Lasting effects and long-term sequelae could persist after the infection and may be due to persistent endothelial dysfunction. Our study focused on the evaluation of endothelial quality index (EQI) by finger thermal monitoring with E4 diagnosis Polymath in a large cohort of long COVID-19 patients to determine whether long-covid 19 symptoms are associated with endothelial dysfunction...Learn More
S. Charfessdine & al : Sulodexide in the treatment of patients with long COVID 19 symptoms and endothelial dysfunction: The results of TUN-EndCOV study
We conducted a prospective multicenter longitudinal case-control study. Endothelial function was evaluated with DTM “E4-Diagnose” Polymath based on the Endothelium Quality Index (EQI). A group of patients with endothelial dysfunction (EQI < 2.0) received sulodexide. All the patients were followed-up 21 days after inclusion. Primary outcomes were defined as endothelial function amelioration (delta EQI) and long COVID-19 symptoms evolution during the follow-up...Learn More
Slim Torjmen : Prévalence, Facteurs Associés et Evolution de la Dysfonction Endothéliale au cours du Long-Covid.